1. "Molecular Pharmacology and Chemistry Program Faculty"
Formats
  1. Journal Article (4957)
  2. Meeting Abstract (2007)
  3. Book Section (216)
  4. Conference Paper (122)
  5. Review (79)
  6. Editorial (48)
  7. Book Whole (28)
  8. Research Letter (15)
  9. Correspondence (8)
  10. Miscellaneous (6)
  11. Guidelines (1)
Groups
  1. Molecular Pharmacology and Chemistry Program Faculty (7487)
  2. Sloan Kettering Institute Faculty (7487)
  3. GSK Faculty (4697)
  4. Department of Medicine (2717)
  5. Surgery (2096)
  6. Center for Hematologic Malignancies (1819)

More Groups

People
  1. Murray Brennan (1059)
  2. Steven Larson (957)
  3. Peter Scardino (671)
  4. Michel Sadelain (582)
  5. Samuel Danishefsky (539)
  6. David Scheinberg (499)

More People

Years
  1. 2025 (36)
  2. 2024 (94)
  3. 2023 (122)
  4. 2022 (150)
  5. 2021 (154)
  6. 2020 (162)

More Years

Publications
  1. Journal of Nuclear Medicine (382)
  2. Blood (379)
  3. Cancer Research (340)
  4. Journal of Clinical Oncology (315)
  5. Annals of Surgical Oncology (181)
  6. International Journal of Radiation Oncology, Biology, Physics (176)

More Publications

Publishers
  1. American Association for Cancer Research (712)
  2. Elsevier Inc. (693)
  3. Nature Publishing Group (490)
  4. Springer (467)
  5. American Chemical Society (440)
  6. Elsevier Science, Inc. (405)

More Publishers

Results (7487)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Overcoming heterogeneity in AML with a novel or-gated HITCAR-1XX platform
    Meeting Abstract

    Haubner, S.; Mansilla-Soto, J.; Garcia Angus, A.; Chang, Q.; De Stanchina, E.; Sadelain, M.
    Blood (2022)

    Fulltext@MSK | Save
  • Target densities in malignant and normal cells determine CAR T cell efficacy and off-target hematotoxicity
    Meeting Abstract

    Haubner, S.; Mansilla-Soto, J.; Nataraj, S.; Kogel, F.; Chang, Q.; De Stanchina, E.; Fraser, K.; Park, J. H.; Wang, X.; Rivière, I.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • A phase I study of CD19-targeted 19(T2)28z1XX CAR T cells in adult patients with relapsed or refractory diffuse large B-cell lymphoma
    Meeting Abstract

    Park, J. H.; Palomba, M. L.; Rivière, I.; Sikder, D. S.; Senechal, B.; Wang, X.; Bermudez, V. P.; Cathcart, E. R.; Liotta, K.; Joseph, J.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Dual IKZF2, and CK1α degrader targets acute myeloid leukemia cells
    Meeting Abstract

    Park, S. M.; Miyamoto, D.; Han, G.; Chan, M.; Curnutt, N.; Tran, N.; Velleca, A.; Kim, J. H.; Schurer, A.; Chang, K.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Genetic ablation of adhesion ligands effectively averts rejection of allogeneic immune cells
    Meeting Abstract

    Hammer, Q.; Perica, K.; Mbofung, R. M.; Van Ooijen, H.; Goodridge, J. P.; Valamehr, B.; Önfelt, B.; Sadelain, M.; Malmberg, K. J.
    European Journal of Immunology (2022)

    Fulltext@MSK | Save
  • Establishment of efficacy of DOTA-based pretargeted radioimmunotherapy with a bivalent radiohapten for enhanced therapeutic indices
    Meeting Abstract

    Vaughn, B.; Veach, D.; Vargas, D. B.; Seo, S.; Punzalan, B.; Zanzonico, P.; Xu, H.; Guo, H. F.; Yang, G.; Ouerfelli, O.; more...
    Journal of Nuclear Medicine (2022)

    Fulltext@MSK | Save
  • Ultrasmall folate receptor alpha targeted enzymatically cleavable silica nanoparticle drug conjugates augment penetration and therapeutic efficacy in models of cancer
    Journal Article

    Wu, F.; Chen, P. M.; Gardinier, T. C.; Turker, M. Z.; Venkatesan, A. M.; Patel, V.; Khor, T.; Bradbury, M. S.; Wiesner, U. B.; Adams, G. P.; more...
    ACS Nano (2022)

    Fulltext@MSK | Save
  • Increased tumor glycolysis is associated with decreased immune infiltration across human solid tumors
    Journal Article

    Cohen, I. J.; Pareja, F.; Socci, N. D.; Shen, R.; Doane, A. S.; Schwartz, J.; Khanin, R.; Morris, E. A.; Sutton, E. J.; Blasberg, R. G.
    Frontiers in Immunology (2022)

    Fulltext@MSK | Save
  • Phase 1 study of intraventricular (131)I-omburtamab targeting B7H3 (CD276)-expressing CNS malignancies
    Meeting Abstract

    Modak, S.; Pandit Taskar, N.; Kushner, B.; Zanzonico, P.; Humm, J.; Donzelli, M.; Lewis, J.; Lyashchenko, S.; Chu, B.; Larson, S.; more...
    Pediatric Blood and Cancer (2022)

    Fulltext@MSK | Save
  • Clinicopathologic characterization of ERK2 E322K mutation in solid tumors: Implications for treatment and drug development
    Meeting Abstract

    Liu, D.; Murciano-Goroff, Y. R.; Jee, J.; Arcila, M. E.; Buonocore, D. J.; Gao, J.; Chakravarty, D.; Schram, A. M.; Callahan, M. K.; Friedman, C. F.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save